News Financials About Visit Website Latest News BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia BioCorRx Reports Business Update for 2023 Apr. 2, 2024 8:30 AM ET BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD Feb. 28, 2024 10:52 AM ET BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors Feb. 8, 2024 9:58 AM ET More News Financials About Contact 714-462-4884 Visit Website BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President Jan. 9, 2024 8:30 AM ET BioCorRx Reports Business Update for the Third Quarter of 2023 Nov. 14, 2023 12:54 PM ET BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder Aug. 15, 2023 9:00 AM ET BioCorRx Reports Business Update for the Second Quarter of 2023 Aug. 14, 2023 4:41 PM ET BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder Jul. 18, 2023 8:30 AM ET BioCorRx Provides Business Update for the First Quarter of 2023 May. 16, 2023 8:30 AM ET BioCorRx Provides Business Update for 2022 Apr. 3, 2023 8:30 AM ET BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting Mar. 7, 2023 3:18 PM ET BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data Feb. 23, 2023 8:30 AM ET BioCorRx to Present at Sequire Biotechnology Conference on February 2nd Jan. 27, 2023 8:30 AM ET BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors Jan. 24, 2023 9:00 AM ET BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Jan. 19, 2023 8:30 AM ET BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States Dec. 7, 2022 9:00 AM ET BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc. Nov. 22, 2022 9:00 AM ET BioCorRx Provides Business Update for the Third Quarter of 2022 Nov. 15, 2022 9:00 AM ET BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Oct. 13, 2022 8:30 AM ET BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference Sep. 6, 2022 8:30 AM ET BioCorRx Provides Business Update for the Second Quarter of 2022 Aug. 16, 2022 8:30 AM ET BioCorRx to Participate in the Benzinga All Access Event on July 15th Jul. 13, 2022 8:30 AM ET BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Jun. 30, 2022 9:00 AM ET BioCorRx Featured on LiveNOW from FOX Jun. 17, 2022 9:00 AM ET BioCorRx to Present at the LD Micro Invitational XII on June 7th May. 31, 2022 9:00 AM ET BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting May. 19, 2022 8:00 AM ET BioCorRx Business Update for the First Quarter of 2022 May. 17, 2022 8:30 AM ET BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Apr. 27, 2022 8:30 AM ET BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Apr. 11, 2022 8:30 AM ET BioCorRx Provides 2021 Year-End Business Update Apr. 1, 2022 8:30 AM ET BioCorRx to Participate in Two Upcoming Conferences Mar. 22, 2022 8:30 AM ET BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder Mar. 16, 2022 9:00 AM ET BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104 Feb. 14, 2022 8:30 AM ET BioCorRx to Present at the H.C. Wainwright BioConnect 2022 Conference Jan. 5, 2022 9:00 AM ET BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board Dec. 9, 2021 9:00 AM ET BioCorRx to Participate in the Benzinga All Access Event on December 2nd Nov. 24, 2021 8:30 AM ET BioCorRx Acquires Intellectual Property for Drug Delivery Nov. 22, 2021 9:15 AM ET BioCorRx Provides Business Update for the Third Quarter of 2021 Nov. 16, 2021 9:15 AM ET BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant Oct. 7, 2021 8:30 AM ET BioCorRx to Present at LD Micro Main Event on Tuesday, October 12th Sep. 29, 2021 12:19 PM ET BioCorRx Files Patent Application with USPTO for Naltrexone Implant Sep. 22, 2021 8:30 AM ET Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Sep. 8, 2021 7:00 AM ET BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Sep. 1, 2021 8:30 AM ET BioCorRx Provides Business Update for the Second Quarter of 2021 Aug. 16, 2021 8:30 AM ET BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board Jun. 22, 2021 8:30 AM ET BioCorRx Provides Business Update for the First Quarter of 2021 May. 18, 2021 9:00 AM ET BioCorRx Receives FDA Clearance of Investigational New Drug (IND) Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder May. 10, 2021 8:30 AM ET BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone Apr. 13, 2021 8:00 AM ET BioCorRx Provides 2020 Year-End Business Update Apr. 1, 2021 8:30 AM ET BioCorRx Completes $2.25 Million Private Placement Mar. 2, 2021 9:28 AM ET BioCorRx Appoints Finance Veteran Joseph J. Galligan to the Board of Directors Feb. 24, 2021 8:30 AM ET BioCorRx Announces Update on NIDA Grant and Development of Naltrexone Implant for the Treatment of Opioid and Alcohol Use Disorders Jan. 15, 2021 8:30 AM ET BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study Nov. 16, 2020 8:30 AM ET BioCorRx Partners with Truusight Health to Integrate Recovery Program Into Self-Funded Health Plans Oct. 13, 2020 8:30 AM ET BioCorRx Provides Business Update for the Second Quarter of 2020 Aug. 14, 2020 8:30 AM ET BioCorRx Provides Update on Current Business Operations and on GLP Studies of BICX102; Uninterrupted by COVID-19 Pandemic May. 22, 2020 8:30 AM ET BioCorRx Offers Free Access to the UnCraveRx Mobile Platform for Weight Loss Management During COVID-19 Pandemic Apr. 10, 2020 8:30 AM ET BioCorRx Offers Free Access to the BioCorRx Recovery Program Mobile Platform for Medical Professionals During COVID-19 Pandemic Apr. 7, 2020 10:26 AM ET BioCorRx Provides Business Update; Pivotal GLP Study of BICX102 Uninterrupted by COVID-19 Pandemic Mar. 31, 2020 8:30 AM ET BioCorRx Announces Senior Management Promotions Mar. 2, 2020 9:15 AM ET BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder Jan. 30, 2020 9:39 AM ET BioCorRx Provides 2019 Year-End Business Update Dec. 19, 2019 8:30 AM ET BioCorRxs Subsidiary, BioCorRx Pharmaceuticals Provides Update on Potential Overdose Reversal Drug Candidate VDM-001 Dec. 3, 2019 8:30 AM ET BioCorRx Announces UnCraveRx a Medically-Assisted Weight Loss Program as Sponsor and Exhibitor at the 36th Annual American Society of Metabolic and Bariatric Society Meeting Oct. 30, 2019 8:30 AM ET BioCorRx Announces the Official Launch of UnCraveRx, a Medically-Assisted Weight Loss Management Program Oct. 8, 2019 8:30 AM ET BioCorRx Announces Capital Restructuring and Provides Business Update Oct. 7, 2019 8:30 AM ET BioCorRx's Director Louis Lucido Appeared Today on Yahoo Finance LIVE On the Move Jul. 22, 2019 2:12 PM ET BioCorRx Announces the Launch of UnCraveRx On-Demand Virtual Fitness, Lifestyle Support and Nutrition App Jul. 22, 2019 8:30 AM ET BioCorRx, Inc. Announces Launch of Pilot Program with Louisiana Department of Corrections for Offenders Suffering with Alcohol and Opioid Use Disorders May. 2, 2019 8:00 AM ET BioCorRx Inc. Unveils New UnCraveRx Weight Loss Program; Appoints Notable Dr. Kenneth Orbeck as Medical Director May. 1, 2019 8:30 AM ET BioCorRx to Present at the Planet MicroCap Showcase 2019 on May 1st in Las Vegas Apr. 30, 2019 9:57 AM ET Joseph J. Galligan Appointed as Senior Advisor to BioCorRx Inc. Apr. 4, 2019 7:30 AM ET BioCorRx Announces Above Market $6 Million Private Placement at $15 Per Share Apr. 2, 2019 7:30 AM ET BioCorRx's Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida Mar. 28, 2019 8:00 AM ET BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement Mar. 27, 2019 7:00 AM ET BioCorRx to Present at the 31st Annual ROTH Conference on March 17-19, 2019 Mar. 14, 2019 8:00 AM ET BioCorRx Partners with IRISYS for Manufacturing of BICX102 Naltrexone Implant for Treatment of Opioid Use Disorder Feb. 26, 2019 8:00 AM ET BioCorRx Appoints Two Finance Veterans to the Board of Directors Feb. 25, 2019 8:00 AM ET BioCorRx Announces Formation of Scientific Advisory Board Feb. 19, 2019 10:29 AM ET BioCorRx Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market Jan. 23, 2019 8:00 AM ET BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder Jan. 22, 2019 7:30 AM ET BioCorRx Provides Business Update for the Third Quarter of 2018 Nov. 14, 2018 8:00 AM ET BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families Oct. 19, 2018 7:30 AM ET BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001 Oct. 9, 2018 8:00 AM ET BioCorRx to Exhibit at the International Association of Chiefs of Police 2018 Annual Conference in Orlando, Florida Oct. 5, 2018 7:30 AM ET BioCorRx Provides BICX102 Grant Update Oct. 2, 2018 7:55 AM ET BioCorRx CEO Brady Granier Discusses BioCorRx Recovery Program on This Life #YouLive Podcast Hosted by Dr. Drew Sep. 25, 2018 11:21 AM ET BioCorRx to Exhibit at the 2nd Annual National Opioid Crisis Management Congress Sep. 20, 2018 9:00 AM ET Actor Jeremy Miller Appears on Local ABC News Supporting BioCorRx Recovery Program Sep. 12, 2018 7:30 AM ET BioCorRx Provides Business Update for the Second Quarter of 2018 Aug. 15, 2018 8:00 AM ET BioCorRx Provides Update on BICX102 Aug. 7, 2018 7:30 AM ET BioCorRx Raises $1.1 Million at Premium to Market Jun. 6, 2018 7:00 AM ET BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102 May. 22, 2018 7:30 AM ET BioCorRx Provides Business Update for the First Quarter of 2018 May. 21, 2018 7:30 AM ET BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant Apr. 30, 2018 7:00 AM ET BioCorRx CEO Brady Granier and Actor Jeremy Miller Appear on Varney & Co. on Fox Business to Discuss the Company's Sustained Release Naltrexone Implant for Alcohol Use Disorder Apr. 26, 2018 8:57 AM ET BioCorRx to Participate in the First Annual Orange County Recovery Collaborative Resource Fair Apr. 13, 2018 8:19 AM ET BioCorRx to Exhibit at ASAM 49th Annual Conference in San Diego, California Apr. 10, 2018 7:30 AM ET BioCorRx CEO Brady Granier and Legendary Soul Man Sam Moore Appear on Fox Business Network to Discuss the Company's Naltrexone Implant, Which Helps Combat Opioid Addiction Apr. 9, 2018 12:30 PM ET
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD Feb. 28, 2024 10:52 AM ET
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors Feb. 8, 2024 9:58 AM ET
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President Jan. 9, 2024 8:30 AM ET
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder Aug. 15, 2023 9:00 AM ET
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder Jul. 18, 2023 8:30 AM ET
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting Mar. 7, 2023 3:18 PM ET
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data Feb. 23, 2023 8:30 AM ET
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors Jan. 24, 2023 9:00 AM ET
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Jan. 19, 2023 8:30 AM ET
BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States Dec. 7, 2022 9:00 AM ET
BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc. Nov. 22, 2022 9:00 AM ET
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Oct. 13, 2022 8:30 AM ET
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference Sep. 6, 2022 8:30 AM ET
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Jun. 30, 2022 9:00 AM ET
BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting May. 19, 2022 8:00 AM ET
BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Apr. 27, 2022 8:30 AM ET
BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Apr. 11, 2022 8:30 AM ET
BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder Mar. 16, 2022 9:00 AM ET
BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104 Feb. 14, 2022 8:30 AM ET
BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board Dec. 9, 2021 9:00 AM ET
BioCorRx Files Patent Application with the Russian Patent Office (Rospatent) for Naltrexone Implant Oct. 7, 2021 8:30 AM ET
Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Sep. 8, 2021 7:00 AM ET
BioCorRx Announces Award of Approximately $3.5 Million NIDA Grant for the Clinical Trial of BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder Sep. 1, 2021 8:30 AM ET
BioCorRx Receives FDA Clearance of Investigational New Drug (IND) Application for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder May. 10, 2021 8:30 AM ET
BioCorRx Announces Submission of IND Application to the FDA for BICX104, Implantable Naltrexone Apr. 13, 2021 8:00 AM ET
BioCorRx Appoints Finance Veteran Joseph J. Galligan to the Board of Directors Feb. 24, 2021 8:30 AM ET
BioCorRx Announces Update on NIDA Grant and Development of Naltrexone Implant for the Treatment of Opioid and Alcohol Use Disorders Jan. 15, 2021 8:30 AM ET
BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study Nov. 16, 2020 8:30 AM ET
BioCorRx Partners with Truusight Health to Integrate Recovery Program Into Self-Funded Health Plans Oct. 13, 2020 8:30 AM ET
BioCorRx Provides Update on Current Business Operations and on GLP Studies of BICX102; Uninterrupted by COVID-19 Pandemic May. 22, 2020 8:30 AM ET
BioCorRx Offers Free Access to the UnCraveRx Mobile Platform for Weight Loss Management During COVID-19 Pandemic Apr. 10, 2020 8:30 AM ET
BioCorRx Offers Free Access to the BioCorRx Recovery Program Mobile Platform for Medical Professionals During COVID-19 Pandemic Apr. 7, 2020 10:26 AM ET
BioCorRx Provides Business Update; Pivotal GLP Study of BICX102 Uninterrupted by COVID-19 Pandemic Mar. 31, 2020 8:30 AM ET
BioCorRx Announces Award of $2.8 Million, the Second Tranche of a NIDA Grant for the Development of BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder Jan. 30, 2020 9:39 AM ET
BioCorRxs Subsidiary, BioCorRx Pharmaceuticals Provides Update on Potential Overdose Reversal Drug Candidate VDM-001 Dec. 3, 2019 8:30 AM ET
BioCorRx Announces UnCraveRx a Medically-Assisted Weight Loss Program as Sponsor and Exhibitor at the 36th Annual American Society of Metabolic and Bariatric Society Meeting Oct. 30, 2019 8:30 AM ET
BioCorRx Announces the Official Launch of UnCraveRx, a Medically-Assisted Weight Loss Management Program Oct. 8, 2019 8:30 AM ET
BioCorRx's Director Louis Lucido Appeared Today on Yahoo Finance LIVE On the Move Jul. 22, 2019 2:12 PM ET
BioCorRx Announces the Launch of UnCraveRx On-Demand Virtual Fitness, Lifestyle Support and Nutrition App Jul. 22, 2019 8:30 AM ET
BioCorRx, Inc. Announces Launch of Pilot Program with Louisiana Department of Corrections for Offenders Suffering with Alcohol and Opioid Use Disorders May. 2, 2019 8:00 AM ET
BioCorRx Inc. Unveils New UnCraveRx Weight Loss Program; Appoints Notable Dr. Kenneth Orbeck as Medical Director May. 1, 2019 8:30 AM ET
BioCorRx to Present at the Planet MicroCap Showcase 2019 on May 1st in Las Vegas Apr. 30, 2019 9:57 AM ET
BioCorRx Announces Above Market $6 Million Private Placement at $15 Per Share Apr. 2, 2019 7:30 AM ET
BioCorRx's Subsidiary, BioCorRx Pharmaceuticals, to Exhibit at ASAM 50th Annual Conference in Orlando, Florida Mar. 28, 2019 8:00 AM ET
BioCorRx Promotes Dr. Balbir S. Brar to Senior VP of Drug Development; Extends Service Agreement Mar. 27, 2019 7:00 AM ET
BioCorRx Partners with IRISYS for Manufacturing of BICX102 Naltrexone Implant for Treatment of Opioid Use Disorder Feb. 26, 2019 8:00 AM ET
BioCorRx Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market Jan. 23, 2019 8:00 AM ET
BioCorRx Awarded NIDA Grant of Approximately $5.7 Million for BICX102, a Sustained Release Naltrexone Implant for the Treatment of Opioid Use Disorder Jan. 22, 2019 7:30 AM ET
BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families Oct. 19, 2018 7:30 AM ET
BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001 Oct. 9, 2018 8:00 AM ET
BioCorRx to Exhibit at the International Association of Chiefs of Police 2018 Annual Conference in Orlando, Florida Oct. 5, 2018 7:30 AM ET
BioCorRx CEO Brady Granier Discusses BioCorRx Recovery Program on This Life #YouLive Podcast Hosted by Dr. Drew Sep. 25, 2018 11:21 AM ET
BioCorRx to Exhibit at the 2nd Annual National Opioid Crisis Management Congress Sep. 20, 2018 9:00 AM ET
Actor Jeremy Miller Appears on Local ABC News Supporting BioCorRx Recovery Program Sep. 12, 2018 7:30 AM ET
BioCorRx Announces Grant Submission to the National Institutes of Health for BICX102 May. 22, 2018 7:30 AM ET
BioCorRx Gains Additional Media Coverage from Fox Medical Correspondent Who Discusses the Advantages of the Naltrexone Implant Apr. 30, 2018 7:00 AM ET
BioCorRx CEO Brady Granier and Actor Jeremy Miller Appear on Varney & Co. on Fox Business to Discuss the Company's Sustained Release Naltrexone Implant for Alcohol Use Disorder Apr. 26, 2018 8:57 AM ET
BioCorRx to Participate in the First Annual Orange County Recovery Collaborative Resource Fair Apr. 13, 2018 8:19 AM ET
BioCorRx CEO Brady Granier and Legendary Soul Man Sam Moore Appear on Fox Business Network to Discuss the Company's Naltrexone Implant, Which Helps Combat Opioid Addiction Apr. 9, 2018 12:30 PM ET
